Tag - Ed Arce

Markets

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

H.C. Wainwright more than doubled the price target for Arcturus Therapeutics (NASDAQ:ARCT) to $62 from $26, citing impressive preclinical results from its COVID-19 vaccine candidate. Shares of Arcturus jumped $7.96, to...

April 28, 2020

Markets

HCW cuts Entasis Therapeutics PT to $5 from $18 on dilution

H.C. Wainwright slashed its price target for Entasis Therapeutics (NASDAQ:ETTX) to $5 from $18, but maintained its “buy” rating, citing a major financing that carries substantial dilution. The stock closed at $2.64 on...

April 14, 2020

Markets

HCW cuts Iterum Therapeutics PT to $9 from $14

H.C. Wainwright lowered its price target for Iterum Therapeutics (NASDAQ:ITRM) to $9 from $14 after the company unveiled a $52-million private placement of exchangeable and royalty-linked subordinated notes earlier this...

January 31, 2020

Tag - Ed Arce

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

HCW cuts Entasis Therapeutics PT to $5 from $18 on dilution

HCW cuts Iterum Therapeutics PT to $9 from $14

General

More